There are currently 497 clinical trials in Lexington, Kentucky looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Kentucky, University of Kentucky/Markey Cancer Center, Saint Joseph Hospital East and Baptist Health Lexington. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer
NCT05221840
Recruiting
This is a Phase III, randomised, double-blind, multicentre, international study assessing the efficacy and safety of durvalumab (MEDI4736) in combination with oleclumab (MEDI9447) or durvalumab (MEDI4736) with monalizumab (IPH2201) in adults with locally advanced (Stage III), unresectable NSCLC, who have not progressed following platinum-based cCRT.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/09/2025
Locations: Research Site, Lexington, Kentucky
Conditions: Non-Small Cell Lung Cancer
Register for Updates
A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.
NCT06268873
Recruiting
The purpose of this study is to measure the efficacy and safety of baxdrostat/dapagliflozin in participants ≥ 18 years of age with CKD and HTN. This study consists of a screening, a 4-week dapagliflozin run-in period for participants naïve to SGLT2i at baseline; a 24-month double-blind period in which participants will receive either baxdrostat/dapagliflozin or dapagliflozin; and a 6-week open-label period in which all participants will discontinue baxdrostat/placebo and receive dapagliflozin a... Read More
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
05/09/2025
Locations: Research Site, Lexington, Kentucky
Conditions: Chronic Kidney Disease and Hypertension
Register for Updates
Pentoxifylline in Diabetic Kidney Disease
NCT03625648
Recruiting
Pentoxifylline (PTX) is a medication that has been on the market since 1984 for use in disease in the blood vessels of the legs. There is some preliminary information that it may protect the kidneys from damage due to diabetes and other diseases. "Pentoxifylline in Diabetic Kidney Disease" is a study to bee conducted in 40 VA hospitals across the nation to determine definitively whether or not PTX can prevent worsening of kidney disease and delay death in patients with diabetic kidney disease.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/09/2025
Locations: Lexington VA Medical Center, Lexington, KY, Lexington, Kentucky
Conditions: Diabetic Kidney Disease
Register for Updates
Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation
NCT05609578
Recruiting
Study CA239-0010 is an open-label, Phase 2 clinical trial evaluating the clinical efficacy of adagrasib in combination with pembrolizumab and chemotherapy in the first-line setting for patients with advanced NSCLC with TPS ≥ 1%, TPS \<50% and KRAS G12C mutation
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/09/2025
Locations: Local Institution - 017-965, Lexington, Kentucky
Conditions: Advanced NSCLC, Metastatic Lung Cancer
Register for Updates
53-Week Study Evaluating the Safety and Efficacy of Intra-articular Injections of TPX-100 With Mild to Severe Tibio-Femoral Osteoarthritis of the Knee
NCT06865079
Recruiting
53-Week Study Evaluating the Safety and Efficacy of Intra-articular (IA) Injections of TPX-100 vs Placebo in Subjects with Mild to Severe Tibio-Femoral Osteoarthritis of the Knee
Gender:
ALL
Ages:
Between 50 years and 80 years
Trial Updated:
05/09/2025
Locations: AMR Lexington, Lexington, Kentucky
Conditions: Osteoarthritis (OA) of the Knee
Register for Updates
Frespaciguat INSIGNIA-PH-COPD: A Study of the Efficacy and Safety of Frespaciguat (an Inhaled sGC Stimulator) in Adults With PH-COPD
NCT05612035
Recruiting
Researchers are looking for ways to treat pulmonary hypertension (PH) caused by chronic obstructive pulmonary disease (COPD). The goal of the study is to learn if people who take frespaciguat can walk farther in 6 minutes at Week 24 compared to people who take placebo.
Gender:
ALL
Ages:
Between 40 years and 85 years
Trial Updated:
05/09/2025
Locations: Lexington VA Medical Center - Cooper Division ( Site 0137), Lexington, Kentucky
Conditions: Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease
Register for Updates
First in Human Study of TORL-1-23 in Participants With Advanced Cancer
NCT05103683
Recruiting
This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-1-23 in patients with advanced cancer
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/09/2025
Locations: University of Kentucky Medical Center, Lexington, Kentucky
Conditions: Advanced Solid Tumor, Ovarian Cancer, Endometrial Cancer, NSCLC
Register for Updates
A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features
NCT06564844
Recruiting
This is a Phase III, randomised, open-label, multicentre, global study assessing the efficacy and safety of adjuvant Dato-DXd in combination with rilvegostomig compared with SoC, after complete surgical resection (R0) in participants with Stage I adenocarcinoma NSCLC who are ctDNA-positive, as determined by the Sponsor-designated ctDNA assay, or have at least one high-risk pathological feature.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/08/2025
Locations: Research Site, Lexington, Kentucky
Conditions: Non-small Cell Lung Cancer
Register for Updates
A Phase 2 Basket Study of Vosoritide in Children With Turner Syndrome, SHOX Deficiency and Noonan Syndrome With an Inadequate Response to Human Growth Hormone
NCT06668805
Recruiting
The purpose of this basket study in children with Turner syndrome, SHOX deficiency, and Noonan syndrome is to evaluate the effect of 3 doses of vosoritide versus hGH on growth as measured by AGV after 6 months of treatment. The long-term efficacy and safety of vosoritide at the therapeutic dose will be evaluated up to FAH.
Gender:
ALL
Ages:
Between 3 years and 11 years
Trial Updated:
05/08/2025
Locations: Kentucky Children's Hospital, Lexington, Kentucky
Conditions: Short Stature Homeobox- Containing Gene SHOX Deficiency, Noonan Syndrome, Turner Syndrome
Register for Updates
Restoration of Hypoglycemia Awareness With Metoclopramide
NCT03970720
Recruiting
Metoclopramide is a drug approved by the FDA for gastroesophageal reflux and to relieve symptoms in adults with acute and recurrent diabetic gastroparesis. The objective of this study is to determine whether metoclopramide can improve hypoglycemia awareness and decrease the incidence of hypoglycemia in type 1 diabetes patients with hypoglycemia unawareness.
Gender:
ALL
Ages:
Between 20 years and 60 years
Trial Updated:
05/08/2025
Locations: University of Kentucky, Lexington, Kentucky
Conditions: Hypoglycemia Unawareness
Register for Updates
MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)
NCT06128629
Recruiting
To evaluate the efficacy and safety of a single dose of NTLA-2001 compared to placebo in participants with ATTR-CM.
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
05/08/2025
Locations: University of Kentucky Gill Heart Institute, Lexington, Kentucky
Conditions: Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
Register for Updates
A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of ANX007 in Participants With Geographic Atrophy (GA)
NCT06510816
Recruiting
The primary purpose of the study is to determine if IVT injections of ANX007 every month reduce vision loss in participants with GA secondary to age-related macular degeneration (AMD).
Gender:
ALL
Ages:
50 years and above
Trial Updated:
05/08/2025
Locations: Retina Associates of Kentucky, Lexington, Kentucky
Conditions: Geographic Atrophy
Register for Updates